Brief: Transgene Provides Q1 2023 Financial Position
May 10 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE PROVIDES BUSINESS UPDATE AND Q1 2023 FINANCIAL
POSITION
* EUR 17.0 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH
31,
2023
* FINANCIAL VISIBILITY UNTIL EARLY 2024
* DR. ALESSANDRO RIVA, MD, APPOINTED AS COMPANY'S CHAIRMAN
AND CEO
Source text for Eikon: ID:nBw2cfrsga
Further company coverage: TRNG.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs